Injectable sponges stop noncompressible bleeding
This article was originally published in Start Up
RevMedx Inc. received FDA de novo approval in April for battlefield use of XStat, which treats noncompressible bleeding from internal wounds. The injectable sponges of XStat expand upon contact with blood to fill the wound cavity, thus creating a temporary barrier and providing hemostatic pressure until hospital care can be rendered.
You may also be interested in...
Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.